Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.RegeneRx Biopharmaceuticals has received positive results from a preclinical study showing that its thymosin beta 4 treatment can decrease corneal inflammation and help restore vision damaged as a result of eye injury.
Subscribe to our email newsletter
The study carried out at Wayne State University and the Kresge Eye Institute in Detroit has shown in laboratory animals that thymosin beta 4 (TB4) treatment promotes corneal wound repair by decreasing corneal inflammation and restoring clarity after an eye injury.
“We have begun to describe TB4’s ability to modulate MMP-9 levels in the cornea and that is significant because MMP-9 overexpression is often associated with dysregulated inflammation and impaired healing. TB4 treatment restores the clarity of the cornea in our model of injury and these findings translate into the potential for improved visual acuity,” said Dr. Sosne assistant professor of ophthalmology at Wayne State University. “This new data continues to support the use of TB4 to treat eye wounds and we look forward to testing this compound in the clinic.”
RegeneRx is developing TB4 as a platform technology for the treatment of acute and chronic wounds and for a variety of human diseases involving tissue and organ repair under an exclusive world-wide license from the National Institutes of Health.
The company recently received clearance from the FDA for its first three phase II clinical trials in dermal wound healing and has targeted cardiac and ophthalmic wound healing as part of its ongoing clinical development program.